Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of Zosurabalpin in Healthy Participants
NCT04605718Phase 1Completed
- Sponsor
- Roche
- Start
- Dec 2020
- Primary completion
- Mar 2023
- Modality
- Cyclic Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of zosurabalpin in Acinetobacter baumannii infection (6 arms), sponsored by Roche. Primary endpoint: Percentage of Participants with Adverse Events up to 19 months. Started Dec 2020; status: completed.
02
Drugs
zosurabalpin
03
Conditions
Acinetobacter baumannii infection
Beyond the preview
Go deeper on NCT04605718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04605718.